| Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma T Devos, Q Van Thillo, V Compernolle, T Najdovski, M Romano, N Dauby, ... European respiratory journal 59 (2), 2022 | 38 | 2022 |
| A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study T Vanassche, MM Engelen, Q Van Thillo, J Wauters, J Gunst, C Wouters, ... Trials 21, 1-14, 2020 | 20 | 2020 |
| Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma M Vanden Bempt, K Debackere, S Demeyer, Q Van Thillo, N Meeuws, ... Blood, The Journal of the American Society of Hematology 140 (23), 2463-2476, 2022 | 13 | 2022 |
| Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia Q Van Thillo, J De Bie, JA Seneviratne, S Demeyer, S Omari, ... Nature Communications 12 (1), 4164, 2021 | 13 | 2021 |
| Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) I Gyselinck, L Liesenborghs, A Belmans, MM Engelen, A Betrains, ... ERJ open research 8 (1), 2022 | 7 | 2022 |
| Modulation of thromboinflammation in hospitalized COVID‐19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn‐Antico study MM Engelen, Q Van Thillo, A Betrains, I Gyselinck, CP Martens, V Spalart, ... Research and practice in thrombosis and haemostasis 6 (7), e12826, 2022 | 3 | 2022 |
| Correction to: a randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico … T Vanassche, MM Engelen, Q Van Thillo, J Wauters, J Gunst, C Wouters, ... Trials 21, 2020 | 3 | 2020 |
| Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3:: PDGFRB fusion Q Van Thillo, B Dewaele, J De Bie, L Michaux, T Devos, P Vandenberghe British Journal of Haematology 202 (1), e7-e10, 2023 | 1 | 2023 |
| ABERRANT MYCN OVEREXPRESSION DRIVES ONCOGENIC HIJACKING OF EZH2 AS A TRANSCRIPTIONAL ACTIVATOR IN PERIPHERAL T CELL LYMPHOMA M Vanden Bempt, K Debackere, A Veloso, S Demeyer, T Slegers, ... EXPERIMENTAL HEMATOLOGY 124, S51-S51, 2023 | | 2023 |
| 3001–ABERRANT MYCN OVEREXPRESSION DRIVES ONCOGENIC HIJACKING OF EZH2 AS A TRANSCRIPTIONAL ACTIVATOR IN PERIPHERAL T CELL LYMPHOMA. MV Bempt, K Debackere, A Veloso, S Demeyer, T Slegers, Q Van Thillo, ... Experimental Hematology 124, S51, 2023 | | 2023 |
| Oncogenic cooperation in T-cell acute lymphoblastic leukemia: the role of TLX3 and TCF7-SPI1 Q Van Thillo | | 2022 |
| P347: COOPERATION OF TLX3 AND FLT3-ITD IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IS ENHANCED BY TLE4 INACTIVATION Q Van Thillo, L Lauwereins, S Demeyer, S Provost, N Mentens, C de Bock, ... HemaSphere 6, 247-248, 2022 | | 2022 |
| P1297: ABERRANT MYCN EXPRESSION DRIVES ONCOGENIC HIJACKING OF EZH2 AS A TRANSCRIPTIONAL ACTIVATOR IN PERIPHERAL T CELL LYMPHOMA MV Bempt, K Debackere, S Demeyer, Q Van Thillo, N Meeuws, J Cools, ... HemaSphere 6, 1182-1183, 2022 | | 2022 |
